Compare FirstEnergy Corp. (FE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Novavax Inc — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.06B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: FirstEnergy Corp. is far larger — about 20.8× Novavax Inc's market cap, and FirstEnergy Corp. pays a 3.98% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| FE | NVAX | |
|---|---|---|
Market Cap | $27.06B | $1.30B |
Sector | Utilities | Health |
52-Week High | $51.91 | $11.19 |
52-Week Low | $42.83 | $6.22 |
Enterprise Value | $55.98B | $879.40M |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
